# PTC Therapeutics clinical trials: 65 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 65 trials with PTC Therapeutics as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by PTC Therapeutics: 65 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ptc-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 65
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 65, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 21, 2026 | NCT07779616 | Study of PTC844 in Participants With Active Rheumatoid Arthritis | PTC Therapeutics | Phase 2 | Recruiting | Rheumatoid Arthritis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779616) |
| July 2, 2026 | NCT07681713 | Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA) | PTC Therapeutics | Phase 3 | Not yet recruiting | Friedreich's Ataxia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681713) |
| March 8, 2024 | NCT06302348 | A Study of Sepiapterin in Participants With Phenylketonuria (PKU) | PTC Therapeutics | Phase 3 | Recruiting | Phenylketonuria | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06302348) |
| August 25, 2022 | NCT05515536 | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia | PTC Therapeutics | Phase 3 | Active not recruiting | Friedreich Ataxia | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05515536) |
| August 3, 2022 | NCT05485987 | A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | PTC Therapeutics | Phase 2 | Completed | Friedreich Ataxia | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05485987) |
| April 27, 2022 | NCT05349721 | Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS | PTC Therapeutics | Phase 2 | Terminated | Amyotrophic Lateral Sclerosis | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05349721) |
| March 8, 2022 | NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | PTC Therapeutics | Phase 2/3 | Terminated | Leiomyosarcoma | 359 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05269355) |
| February 1, 2022 | NCT05218655 | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease | PTC Therapeutics | Phase 3 | Completed | Inherited Mitochondrial Disease | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05218655) |
| December 21, 2021 | NCT05166161 | A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria | PTC Therapeutics | Phase 3 | Completed | Phenylketonuria | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05166161) |
| October 29, 2021 | NCT05099640 | A Study of PTC923 in Participants With Phenylketonuria | PTC Therapeutics | Phase 3 | Completed | Phenylketonuria | 157 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05099640) |
| May 26, 2021 | NCT04903288 | A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric... | PTC Therapeutics | Phase 2 | Active not recruiting | AADC Deficiency | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04903288) |
| October 6, 2020 | NCT04577352 | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | PTC Therapeutics | Phase 2/3 | Completed | Friedreich Ataxia | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04577352) |
| June 19, 2020 | NCT04439071 | A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) | PTC Therapeutics | Phase 2/3 | Terminated | Pneumonia, COVID-19, Coronavirus | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04439071) |
| May 7, 2020 | NCT04378075 | A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy | PTC Therapeutics | Phase 2/3 | Terminated | Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS)... | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04378075) |
| April 7, 2020 | NCT04336826 | A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to \<2 Years of Age With Nonsense Mutation... | PTC Therapeutics | Phase 2 | Completed | Nonsene Mutation Duchenne Muscular Dystrophy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04336826) |
| October 7, 2019 | NCT04117880 | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia | PTC Therapeutics | Phase 2 | Withdrawn | Aniridia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04117880) |
| January 8, 2019 | NCT03796637 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With... | PTC Therapeutics | Phase 2 | Completed | Duchenne Muscular Dystrophy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03796637) |
| December 21, 2018 | NCT03783923 | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) | PTC Therapeutics | Phase 3 | Terminated | Limb-Girdle Muscular Dystrophy | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03783923) |
| December 3, 2018 | NCT03761095 | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) | PTC Therapeutics | Phase 1 | Completed | Leiomyosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03761095) |
| December 3, 2018 | NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | PTC Therapeutics | Phase 1 | Terminated | Leukemia, Myeloid, Acute, AML | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03761069) |
| October 19, 2018 | NCT03712124 | A Study of CNSA-001 in Women With Diabetic Gastroparesis | PTC Therapeutics | Phase 2 | Completed | Gastroparesis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03712124) |
| August 27, 2018 | NCT03648827 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) | PTC Therapeutics | Phase 2 | Completed | Duchenne Muscular Dystrophy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03648827) |
| August 22, 2018 | NCT03642145 | A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) | PTC Therapeutics | Phase 3 | Withdrawn | Duchenne Muscular Dystrophy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03642145) |
| May 9, 2018 | NCT03519711 | A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia | PTC Therapeutics | Phase 1/2 | Completed | BH4 Deficiency, Hyperphenylalaninemia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03519711) |
| June 7, 2017 | NCT03179631 | Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy | PTC Therapeutics | Phase 3 | Completed | Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal... | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03179631) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 1 |
| Phase 2 | 27 |
| Phase 2/3 | 4 |
| Phase 3 | 18 |
| Not applicable | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 39 |
| Terminated | 17 |
| Recruiting | 2 |
| Active not recruiting | 2 |
| Withdrawn | 2 |
| No longer available | 1 |
| Not yet recruiting | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Muscular Dystrophy, Duchenne | 18 |
| Cystic Fibrosis | 9 |
| Friedreich Ataxia | 6 |
| Leigh Disease | 5 |
| Phenylketonurias | 4 |
| Mitochondrial Diseases | 4 |
| MELAS Syndrome | 3 |
| Muscular Dystrophies | 3 |
| Muscular Disorders, Atrophic | 3 |
| Muscular Diseases | 3 |
| Musculoskeletal Diseases | 3 |
| Neuromuscular Diseases | 3 |
| Nervous System Diseases | 3 |
| Genetic Diseases, X-Linked | 3 |
| Genetic Diseases, Inborn | 3 |
| Neoplasms | 3 |
| Aniridia | 2 |
| Diffuse Cerebral Sclerosis of Schilder | 2 |
| MERRF Syndrome | 2 |
| Drug Resistant Epilepsy | 2 |
| Amyotrophic Lateral Sclerosis | 2 |
| Leiomyosarcoma | 2 |
| Ataxia | 1 |
| Arthritis, Rheumatoid | 1 |
| Autoimmune Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Wine wholesalers in the United States](https://specstream.ai/data/businesses/wine-wholesalers/united-states)
- [Beach resorts in the United States](https://specstream.ai/data/businesses/beach-resorts/united-states)
- [Coworking spaces in the United States](https://specstream.ai/data/businesses/coworking-spaces/united-states)
- [Fitness equipment wholesalers in the United States](https://specstream.ai/data/businesses/fitness-equipment-wholesalers/united-states)
- [Investment management firms in the United States](https://specstream.ai/data/businesses/investment-management-firms/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
